Several GRPR-binding ligands have been developed during the past years, where antagonists have shown to be more beneficial as imaging agents than agonists due to higher tumor accumulation and absence of adverse effects, as well as no downregulation of GRPR or stimulation of tumor growth [13,14]. This evidence concerns the gene GRPR and neoplasm.